Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
218.66
0.00 (0.00%)
At close: Jan 16, 2026, 4:00 PM EST
217.97
-0.69 (-0.32%)
Pre-market: Jan 20, 2026, 8:09 AM EST
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $23.99B in the quarter ending September 28, 2025, with 6.77% growth. This brings the company's revenue in the last twelve months to $92.15B, up 5.08% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$92.15B
Revenue Growth
+5.08%
P/S Ratio
5.71
Revenue / Employee
$667,263
Employees
138,100
Market Cap
526.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | 82.06B | 478.00M | 0.59% |
| Dec 30, 2018 | 81.58B | 5.13B | 6.71% |
| Dec 31, 2017 | 76.45B | 4.56B | 6.34% |
| Jan 1, 2017 | 71.89B | 1.82B | 2.59% |
| Jan 3, 2016 | 70.07B | -4.26B | -5.73% |
| Dec 28, 2014 | 74.33B | 3.02B | 4.23% |
| Dec 29, 2013 | 71.31B | 4.09B | 6.08% |
| Dec 30, 2012 | 67.22B | 2.19B | 3.37% |
| Jan 1, 2012 | 65.03B | 3.44B | 5.59% |
| Jan 2, 2011 | 61.59B | -310.00M | -0.50% |
| Jan 3, 2010 | 61.90B | -1.85B | -2.90% |
| Dec 28, 2008 | 63.75B | 2.65B | 4.34% |
| Dec 30, 2007 | 61.10B | 7.77B | 14.57% |
| Dec 31, 2006 | 53.32B | 2.81B | 5.56% |
| Jan 1, 2006 | 50.51B | 3.17B | 6.69% |
| Jan 2, 2005 | 47.35B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
JNJ News
- 1 day ago - Is Johnson & Johnson A Dividend Stock, Or Something Else? - Seeking Alpha
- 1 day ago - Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade) - Seeking Alpha
- 5 days ago - TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide - PRNewsWire
- 7 days ago - Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting - PRNewsWire
- 7 days ago - Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors - Seeking Alpha
- 7 days ago - Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court - Reuters
- 7 days ago - Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 9 days ago - The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips - Forbes